Kato, Jun



School of Medicine, Department of Internal Medicine (Hematology) (Shinanomachi)


Assistant Professor/Senior Assistant Professor


Papers 【 Display / hide

  • Factors affecting lower limb muscle strength and cardiopulmonary fitness after allogeneic hematopoietic stem cell transplantation

    Ishikawa A., Otaka Y., Kamisako M., Suzuki T., Miyata C., Tsuji T., Matsumoto H., Kato J., Mori T., Okamoto S., Liu M.

    Supportive Care in Cancer (Supportive Care in Cancer)  27 ( 5 ) 1793 - 1800 2019.05

    ISSN  09414355

     View Summary

    © 2018, The Author(s). Purpose: The aim of this study is to clarify the factors affecting physical function after allogeneic hematopoietic stem cell transplantation (HSCT). Methods: We retrospectively analyzed 88 patients (median age, 44.5 years) who received allogeneic HSCT. Leg extension torque and peak oxygen consumption (VO 2 ) were evaluated before and after HSCT. Patient factors (age, sex, underlying diseases, hemoglobin, serum albumin, and Karnofsky performance status score before transplant) and transplant factors (conditioning regimen, days to neutrophil engraftment, grades of acute graft-versus-host disease [GVHD], infections, and the interval between pre- and post-evaluation) were collected via chart review, and were used for correlational and comparison analyses in order to identify the variables associated with reduced post-HSCT leg extension torque and peak VO 2 . Stepwise multiple regression analyses for post-HSCT leg extension torque and post-HSCT peak VO 2 were performed using age, sex, and the related variables with a p value < 0.2 in the correlational and comparison analyses. Results: Leg extension torque and peak VO 2 were significantly reduced after HSCT (p < 0.001). Pre-HSCT leg extension torque, grades of acute GVHD, age, and the interval between pre- and post-evaluation were identified as significant factors associated with reduced post-HSCT leg extension torque. However, none of these factors were significantly associated with reduced post-HSCT peak VO 2 , and only its pre-transplant value was identified as a significant factor. Conclusions: These findings suggest that improvements in muscle strength and cardiopulmonary fitness before HSCT are crucial for maintaining post-treatment physical function, especially in elderly individuals with acute GVHD requiring a long-term stay in a protective environment.

  • Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

    Sakurai M., Kikuchi T., Karigane D., Kasahara H., Matsuki E., Hashida R., Yamane Y., Abe R., Koda Y., Toyama T., Kato J., Shimizu T., Yokoyama Y., Suzuki S., Nakamura T., Okamoto S., Mori T.

    International Journal of Hematology (International Journal of Hematology)  109 ( 3 ) 292 - 298 2019.03

    ISSN  09255710

     View Summary

    © 2019, Japanese Society of Hematology. Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. The mean estimated glomerular filtration rate (eGFR) was significantly decreased over 5 years (77 ± 17 to 62 ± 14 ml/min/1.73m², P < 0.001). Higher age and lower eGFR value at initiation of imatinib were significantly associated with development of renal dysfunction by multivariate analyses. Mean hemoglobin levels also significantly decreased over the 5-year period (12.9 ± 1.7 to 12.4 ± 1.3 g/dl, P < 0.01). The rate of decrease in eGFR correlated significantly with hemoglobin levels (correlation coefficient = − 0.249, P < 0.05). Serum erythropoietin (EPO) levels did not increase in 16 patients with both renal dysfunction and anemia (median, 31.9 mIU/ml). In patients who participated in a clinical trial of imatinib discontinuation, mean eGFR (50.0 ± 6.5 to 56.0 ± 10.2 ml/min/1.73m², P < 0.05) and hemoglobin levels (12.0 ± 1.7 to 14.0 ± 1.6 g/dl, P < 0.01) improved significantly at 1 year after discontinuation. These findings suggest that long-term imatinib results in a partially reversible continuous decline in renal function and decreased hemoglobin levels.

  • Invasive hepatic mucormycosis: A case report and review of the literature

    Karigane D., Kikuchi T., Sakurai M., Kato J., Yamane Y., Hashida R., Abe R., Hatano M., Hasegawa N., Wakayama M., Shibuya K., Okamoto S., Mori T.

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  25 ( 1 ) 50 - 53 2019.01

    ISSN  1341321X

     View Summary

    © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Mucormycosis generally develops under immunocompromised conditions, including hematological malignancies and solid organ or hematopoietic stem cell transplantation. Although mucormycosis usually affects the lungs and paranasal sinuses, sporadic cases of invasive mucormycosis of the liver have been reported. We hereby report a patient with myelofibrosis who developed hepatic mucormycosis diagnosed by post-mortem examination. An extensive literature review identified 13 reported cases of hepatic mucormycosis, including ours, without lung involvement. Most of the underlying diseases or conditions were hematological malignancies and solid organ transplantation. Three cases had splenic lesions and four had gastrointestinal lesions, suggesting the possibility of translocation to the liver and/or spleen from the gastrointestinal tracts. Hepatic mucormycosis should be recognized as one of the presentations of invasive mucormycosis, especially when hepatic nodules are found in immunocompromised patients such as those with hematological malignancy or recipients of solid organ transplantation.

  • Impact of immunoglobulin G2 subclass level on late-onset bacterial infection after allogeneic hematopoietic stem cell transplantation

    Yamazaki R., Kato J., Koda Y., Sakurai M., Tozawa K., Okayama M., Nakayama H., Watanuki S., Kikuchi T., Hasegawa N., Okamoto S., Mori T.

    Transplant Infectious Disease (Transplant Infectious Disease)   2019

    ISSN  13982273

     View Summary

    © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Background: Immunoglobulin (Ig) G2 subclass deficiency is known to be associated with recurrent bacterial respiratory infections caused by capsulated bacteria and is found mostly in pediatric patients. However, its impact after allogeneic hematopoietic stem cell transplantation (HSCT) has not been fully assessed. Methods: We retrospectively evaluated the relationship between IgG2 subclass levels and bacterial pneumonia in 74 adult patients who survived longer than 2 years after allogeneic HSCT. Results: During the evaluation period, nine patients developed bacterial pneumonia. The median IgG2 level was significantly lower in patients with an infectious episode than in those without (143 mg/dL vs 287 mg/dL; P < 0.01). In multivariate analysis, a history of rituximab therapy and cord blood as a stem cell source were significantly associated with decreased levels of both IgG2 and IgG2/IgG ratios (P < 0.05). Conclusions: Suboptimal serum IgG2 levels could increase susceptibility to late-onset bacterial pneumonia after allogeneic HSCT. IgG2 levels should be considered carefully, especially in patients receiving cord blood transplantation and/or rituximab treatment.

  • Successful Steroid Therapy for Lipoid Pneumonia Developing After Allogeneic Hematopoietic Stem Cell Transplant: A Case Report

    Sakurai M., Kato J., Toyama T., Hashida R., Yamane Y., Abe R., Koda Y., Kohashi S., Kikuchi T., Hayashi Y., Nukaga S., Ueda S., Fukunaga K., Okamoto S., Mori T.

    Transplantation Proceedings (Transplantation Proceedings)  50 ( 10 ) 4096 - 4098 2018.12

    ISSN  00411345

     View Summary

    © 2018 Elsevier Inc. Lipoid pneumonia is an uncommon noninfectious inflammatory lung disease characterized by lipid deposition in the alveoli, and its etiology and treatment have not been elucidated. We report the case of a 32-year-old woman who developed lipoid pneumonia 9 months after allogeneic hematopoietic stem cell transplant for chronic myelogenous leukemia in lymphoid blast crisis. She complained of progressive cough and dyspnea shortly after discontinuation of immunosuppressive therapy given for graft-vs-host disease. Computed tomography demonstrated diffuse ground-glass opacities in the lungs, and pulmonary function test revealed restrictive impairment. Bronchoalveolar lavage fluid showed milky appearance, and transbronchial lung biopsy specimen revealed foamy macrophages infiltrating the alveoli. Based on these findings, she was diagnosed as having lipoid pneumonia. Prednisolone (1 mg/kg/d) promptly improved the symptoms, pulmonary shadows, and pulmonary function. The findings and clinical course of this case suggest that lipoid pneumonia should be recognized as one of the pulmonary complications of allogeneic hematopoietic stem cell transplantation.

display all >>

Presentations 【 Display / hide

  • Drug interaction between oral calcineurin inhibitors (tacrolimus and cyclosporine A) and oral voriconazole in the recipients of allogeneic haematopoietic stem cell transplantation.

    MORI TAKEHIKO, kato Jun, Aisa Yoshinobu, Yamane Aakiko, Ono Yukako, Okamoto Shinichiro

    ASBMT/IBMTR Tandem BMT Meetings (Orlando,Florida) , 2010, Poster (general)

  • Evaluation of Optimal Blood Concentration of Tacrolimus for the Prophylaxis of Acute Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donor.

    MORI TAKEHIKO, Aisa Yoshinobu, kato Jun, Nakamura Yukinobu, Ikeda Yasuo, Okamoto Shinichiro

    ASBMT/IBMTR Tandem BMT Meetings (Tampa,Florida) , 2009, Poster (general)

  • 非血縁者間同種骨髄移植後のtacrolimusと短期methotrexate(MTX)を用いた移植片対宿主病予防:tacrolimusの至適血中濃度の検討


    第31回日本造血細胞移植学会総会 (札幌) , 2009, Poster (general)

  • Long-term follow-up after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.

    MORI TAKEHIKO, Aisa Yoshinobu, Kato Jun, Ikeda Yasuo, Okamoto Shinichiro

    ASBMT/IBMTR Tandem BMT Meetings (San Diego,California) , 2008, Poster (general)

  • 急性骨髄性白血病に対する全身放射線照射と顆粒球コロニー刺激因子(G-CSF)併用大量cytarabineを前処置とした同種造血幹細胞移植。


    第30回日本造血細胞移植学会総会 (大阪) , 2008, Poster (general)

display all >>


Courses Taught 【 Display / hide











display all >>